Těžké astma

Postery prezentované na AAAAI Annual Meeting, San Francisco, CA, USA, 22.–25. února, 2019

• Clinically meaningful improvements in asthma control questionnaire (ACQ) scores occur early, while asthma-related quality of life (AQLQ) scores continue to improve over 52 weeks, among patients with eosinophilic asthma receiving IV reslizumab (staženo 63× )

 

• High peripheral blood eosinophil levels are associated with low FEV1 reversibility in patients with severe eosinophilic asthma (staženo 67× )

 

• Evaluation of eosinophilic asthma patients without blood eosinophil (EOS) response to intravenous (IV) reslizumab in a post-hoc analysis of 52-week placebo-controlled Phase 3 studies (staženo 63× )

 

• A high proportion of exacerbation-prone patients with uncontrolled eosinophilic asthma receiving intravenous (IV) reslizumab experienced zero asthma exacerbations through 52 weeks of treatment (staženo 63× )

 

• Variability in absolute blood eosinophil (EOS) counts over 52 weeks in patients with inadequately controlled eosinophilic asthma receiving placebo in two duplicate clinical trials (staženo 60× )

 

Odborné texty

• Monoklonální protilátky v léčbě prednison-dependentního astmatu (staženo 29× )

 

• Luis A. Pérez de Llano et al. Mepolizumab and reslizumab, two different options for severe asthma patients with prior failure to omalizumab (staženo 35× )

 

• Santus, Pierachille et al. Patients beliefs on intravenous and subcutaneous routes of administration of biologics for severe asthma treatment: A cross-sectional observational survey study (staženo 36× )

 

• Secondary loss of response to mepolizumab in severe eosinophilic asthma (staženo 74× )

 

• Novosad J, Krčmová I. Reslizumab. Remedia 2/2019 (staženo 125× )

 

• Weight-adjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed-Dose Subcutaneous Mepolizumab (staženo 100× )

 

• Reslizumab v terapii pacientů s nedostatečně kontrolovaným eozinofilním astmatem (staženo 299× )

 

Prezentace

• Jak přistupovat k léčbě obézních pacientů s těžkým astmatem
  Milan Teřl

• Reslizumab v terapii neatopického eosinofilního astmatu
  Alena Vlachová

• Přínos reslizumabu pro astmatiky s chronickou rinosinusitidou a nazálními polypy
  Irena Krčmová